KR20230125720A - Oral antibacterial composition comprising Torilis japonica extract as effective component - Google Patents

Abstract

The present invention relates to an antibacterial composition for oral cavity containing an extract of Sasang japonica as an active ingredient, and an extract of Sasang japonica of the present invention has antibacterial activity against oral bacteria Streptococcus mutans and Streptococcus sobrinus . Since it is excellent, it can be used very usefully for compositions for inhibiting oral bacteria, pharmaceuticals, and feed additives.

Description

Oral antibacterial composition comprising Torrilis japonica extract as an effective component}

The present invention relates to a composition for oral antibacterial use containing a sandalwood extract as an active ingredient.

Tooth decay is one of the most prevalent oral diseases worldwide, and its morbidity is gradually increasing due to changes in dietary patterns such as increased sugar intake. Dental caries (cavity) is a multifactorial disease caused by the interaction of bacteria, food, and saliva in plaque. Among bacteria in plaque , Streptococcus mutans and Streptococcus sobrinus are the main causes It is a bacterial dental hard tissue disease that attaches to the tooth surface, undergoes proliferation and acid production, demineralizes teeth, and destroys dentin, resulting in loss of tooth tissue. In addition, in order for the organic acid produced by the bacteria causing tooth decay to act directly on the tooth, the acid-producing bacteria must stay on the tooth surface, and for this, insoluble glucan must be formed. GTase (glucosyltransferase) secreted by cariogenic bacteria uses sucrose to form insoluble glucan composed of 90% or more α-1,3 glucosidic linkage and the rest α-1,6 glucosidic linkage as a glucose polymer. . Because it does not dissolve in water and has the ability to adhere to the tooth surface, it forms a bacterial film on the tooth surface and causes early tooth decay.

Various methods have been studied for the development of preventive and therapeutic agents for dental caries (cavities), and an effective method is to suppress tooth decay by inhibiting the production of biofilm formed on teeth. In addition, a method of developing a GTase inhibitor that prevents biofilm formation is one of the frequently used biofilm inhibition methods. However, the most important method for the prevention and treatment of dental caries is the development of antibacterial agents that inhibit the growth of caries-causing bacteria. In particular, the development of antibacterial active preparations using natural extracts with low toxicity and excellent stability is actively progressing. For example, caries inhibitors using aloe extract, kelp extract or Schisandra chinensis extract are being researched and developed. The natural extracts of these edible plants have the advantage of having little toxicity and being easily ingested.

On the other hand, Torilidis Fructus is a fruit of Torilis japonica (Houtt.) DC., a biennial herb of the Apiaceae family (Umbelliferae), and is known to be spicy, bitter, warm, and non-toxic. In oriental medicine, a herbal medicine made from dried fruit is called sasangja, and it is distributed in Korea, Japan, China, Taiwan, India, and Myanmar. Pharmacological effects include antiprotozoal action, sex hormone-like action, and anti-allergic action, and as an astringent anti-inflammatory drug, it is effective for itching. It is reported to contain sesquiterpene-based compounds.

As prior art related to tooth decay, Korean Patent No. 1645936 discloses 'a tooth decay prevention or oral deodorant composition using Yulpi extract as an active ingredient and a manufacturing method thereof', and Korean Patent No. 2155741 discloses 'a persimmon extract as an effective ingredient'. Disclosed is a composition for preventing tooth decay or removing bad breath. However, there has been no disclosure of the 'composition for oral antibacterial use containing an extract of a casualty shooter as an active ingredient' of the present invention.

The present invention has been derived from the above needs, and the present invention provides an oral antibacterial composition containing an extract of the present invention as an active ingredient, and the extract of the present invention is an oral bacterium, Streptococcus mutans ( Streptococcus mutans ) and Streptococcus sobrinus ( Streptococcus sobrinus ) By confirming that the antibacterial activity is excellent, the present invention was completed.

In order to solve the above problems, the present invention provides a composition for inhibiting oral bacteria containing an extract of Torilis japonica as an active ingredient.

In addition, the present invention provides a quasi-drug for preventing or improving oral diseases containing Torilis japonica extract as an active ingredient.

In addition, the present invention provides a pharmaceutical composition for preventing or treating oral diseases containing Torilis japonica extract as an active ingredient.

In addition, the present invention provides a feed additive for preventing or improving oral diseases containing Torilis japonica extract as an active ingredient.

In addition, the present invention provides a veterinary composition for preventing or treating oral diseases containing Torilis japonica extract as an active ingredient.

The present invention relates to an antibacterial composition for oral cavity containing an extract of Sasang japonica as an active ingredient, and an extract of Sasang japonica of the present invention has antibacterial activity against oral bacteria Streptococcus mutans and Streptococcus sobrinus . this is excellent

In order to achieve the object of the present invention, the present invention provides a composition for inhibiting oral bacteria containing Torilis japonica extract as an active ingredient.

The oral bacteria are preferably Streptococcus mutans or Streptococcus sobrinus, more preferably Streptococcus sobrinus , but are not limited thereto.

The casualty extract may be prepared by a method comprising the following steps, but is not limited thereto:

1) extracting by adding an extraction solvent to the casualties;

2) filtering the extract of step 1); and

3) preparing an extract by concentrating the filtered extract of step 2) under reduced pressure and drying it.

In step 1), the extraction solvent is preferably water, C ₁ ~ C ₄ lower alcohol or a mixture thereof, more preferably an ethanol extract, and even more preferably a 70% (v / v) ethanol extract. Not limited.

In the above production method, extraction of casualties may use all conventional methods known in the art, such as filtration, hot water extraction, immersion extraction, reflux cooling extraction and ultrasonic extraction. The vacuum concentration in step 3) is preferably performed using a vacuum vacuum concentrator or a vacuum rotary evaporator, but is not limited thereto. In addition, drying is preferably reduced pressure drying, vacuum drying, boiling drying, spray drying or freeze drying, but is not limited thereto.

The composition for inhibiting oral bacteria may be formulated into a solid, semi-solid, liquid or temperature-sensitive sol-gel phase transition formulation for oral administration or parenteral administration by adding an inorganic or organic carrier. In one embodiment of the present invention, the composition may be prepared in any one formulation selected from the group consisting of mouthwash, mouthwash, toothpaste, oral spray, toothbrush cleaner and denture cleaner, but is not limited thereto.

In addition, the present invention provides a quasi-drug for preventing or improving oral diseases containing Torilis japonica extract as an active ingredient.

It is preferable that the oral disease is tooth decay, but is not limited thereto, and the cavity is preferably tooth decay caused by Streptococcus mutans or Streptococcus sobrinus , but is not limited thereto. .

As used herein, the term “quasi-drugs” refers to textiles, rubber products or similar products used for the purpose of treating, mitigating, treating or preventing diseases of humans or animals, products that have weak effects on the human body or do not directly act on the human body, and devices or non-machines and similar items, products falling under one of the categories of agents used for sterilization, insecticidal, and similar purposes to prevent infection, which are used for the purpose of diagnosing, treating, mitigating, treating, or preventing human or animal diseases It refers to items that are not instruments, machines, or devices, and items other than instruments, machines, or devices that are used for the purpose of pharmacologically affecting the structure and function of humans or animals. Also includes supplies.

When the composition of the present invention is included in a quasi-drug for the purpose of preventing or improving tooth decay, the composition may be included as it is or used together with other quasi-drug ingredients, and may be appropriately used according to a conventional method. The mixing amount of the active ingredient can be suitably determined depending on the purpose of use.

The quasi-drug of the present invention may contain various bases and additives necessary for formulation according to its dosage form, and the type and amount of these components can be easily selected by those skilled in the art. For example, when the formulation of the oral composition is toothpaste, it can be prepared by adding an abrasive, a wetting agent, a foaming agent, a binder, a sweetener, a pH adjusting agent, a preservative, an active ingredient, a flavoring agent, a brightening agent, a coloring agent, and a solvent.

In addition, the present invention provides a pharmaceutical composition for preventing or treating oral diseases containing Torilis japonica extract as an active ingredient.

It is preferable that the oral disease is tooth decay, but is not limited thereto, and the cavity is preferably tooth decay caused by Streptococcus mutans or Streptococcus sobrinus , but is not limited thereto. .

The composition of the present invention may further include a pharmaceutically acceptable carrier, excipient or diluent in addition to the active ingredient.

The extract according to the present invention may be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories and sterile injection solutions according to conventional methods, respectively. there is. Carriers, excipients and diluents that may be included in the extract include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginates, gelatin, calcium phosphate, calcium silicate, cellulose, methyl and various compounds or mixtures including cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. When formulated, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc. These solid preparations contain at least one excipient, for example, starch, calcium carbonate, sucrose, etc., in the extract or fraction. It is prepared by mixing sucrose, lactose, or gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral use include suspensions, solutions for oral use, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included. .

The dosage of the composition of the present invention varies depending on the patient's body weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and severity of the disease. The composition of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modifiers.

In addition, the present invention provides a feed additive for preventing or improving oral diseases containing Torilis japonica extract as an active ingredient.

The feed additive of the present invention corresponds to supplementary feed under the Feed Management Act. In the present invention, the term 'feed' may refer to any natural or artificial diet, one meal, etc., or a component of the one meal meal, suitable for or suitable for consumption by animals. The type of feed is not particularly limited, and feeds commonly used in the art may be used. Non-limiting examples of the feed include vegetable feeds such as grains, root fruits, food processing by-products, algae, fibers, pharmaceutical by-products, oils and fats, starches, meal or grain by-products; Animal feed such as proteins, inorganic materials, oils, mineral oils, oils, single cell proteins, zooplankton, or food may be mentioned. These may be used alone or in combination of two or more.

In addition, the present invention provides a veterinary composition for preventing or treating oral diseases containing Torilis japonica extract as an active ingredient.

The veterinary composition containing the extract of the present invention may further include appropriate excipients and diluents according to conventional methods. Examples of excipients and diluents that may be included in the veterinary composition containing the casualty shoot extract of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, Calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, cetanol, stearyl alcohol, liquid paraffin , sorbitan monostearate, polysorbate 60, methylparaben, propylparaben and mineral oil.

The veterinary composition containing the extract of the present invention may further include a filler, an anti-coagulant, a lubricant, a wetting agent, a spice, an emulsifier, a preservative, and the like, and the veterinary composition according to the present invention is active It can be formulated using methods well known in the art to provide rapid, sustained or delayed release of the ingredients, and the dosage form can be powders, granules, tablets, capsules, suspensions, emulsions, solutions, syrups, aerosols, soft Alternatively, it may be in the form of a hard gelatin capsule, a suppository, a sterile solution for injection, or a sterile external preparation.

The veterinary composition according to the present invention may vary depending on the age, sex, and weight of the animal, but may be administered once or several times a day, and the dosage may increase or decrease depending on the route of administration, severity of disease, sex, weight, age, etc. It can be. Accordingly, the dosage is not intended to limit the scope of the present invention in any way.

Hereinafter, an embodiment of the present invention will be described in detail. However, the following examples are only to illustrate the present invention, and the content of the present invention is not limited to the following examples.

Example 1. Preparation of casualty extract

For 1 kg of the casualty of the present invention, 15 liters of 70% (v / v) ethanol was added, extracted at 85 ° C for 3 hours, and the filtered extract was concentrated under reduced pressure at 45 ° C and dried to obtain a casualty extract (hereinafter referred to as 'sample'). referred to as) was obtained.

Example 2. Antibacterial effect of casualty extract on oral bacteria

Oral bacteria Streptococcus mutans ( Streptococcus mutans ) and Streptococcus sobrinus ( Streptococcus sobrinus ) were used and pre-cultured for 24 hours in BHI (Brain Heart Infusion) liquid medium. Add casualty extract (250 μg/ml) to the BHI broth, inoculate the oral bacterial culture to 1.0×10 ⁸ CFU/mL, and incubate in a thermostat at 37° C. for 24 hours. Molecular Devices Co., CF., USA) was used to measure absorbance at 600 nm, and the growth inhibition of Streptococcus mutans and Streptococcus sobrinus was measured using the following formula.

As a result, as shown in Table 1 below, when the casualty extract was treated, the growth of Streptococcus mutans and Streptococcus sobrinus was inhibited, and in particular, the antibacterial effect against Streptococcus mutans was It was found to be very good compared to

Growth inhibitory activity (%) = {1-(OD ₆₀₀ with sample/OD ₆₀₀ without sample)} × 100

antibacterial effect treatment concentration
(μg/ml) Inhibitory activity (%) Streptococcus sobrinus Streptococcus mutans 250 85.3±0.3 55.7±1.7

Example 3. Inhibitory effect of Sagittarius extract on the attachment of oral bacteria to gingival fibroblasts

Gingival fibroblasts (HGF-1, human gingival fibroblast-1) cells were dispensed at a concentration of 1.0 × 10 ⁴ CFU per well in a 96-well plate, and then treated with the casualty extract of the present invention by concentration to determine whether there was cytotoxicity did Samples were processed at a concentration that did not show cytotoxicity, and 1.0 × 10 ³ CFU per well of Streptococcus mutans ( Streptococcus mutans ) and Streptococcus sobrinus ( Streptococcus sobrinus ) were mixed and inoculated. After 30 minutes, PBS (phosphate-buffered saline ), washed three times with BHI (Brain Heart Infusion) medium, cultured in a 10% CO ₂ incubator for 24 hours, and then the number of bacteria was measured to confirm the adhesion inhibitory activity using the following formula.

Adhesion inhibitory activity (%) = {1-(OD ₆₀₀ with added sample / OD ₆₀₀ without added sample)} × 100

As a result, as shown in Table 2 below, the Sasangia extract was effective in inhibiting the adhesion of the oral bacteria Streptococcus mutans and Streptococcus sobrinus to gingival fibroblasts in a concentration-dependent manner.

adhesion inhibitory effect treatment concentration
(μg/ml) Inhibitory activity (%) 200 88.6±3.1 100 85.6±1.9 50 46.7±0.8

Claims (12)

Sasangja ( Torilis japonica ) A composition for inhibiting oral bacteria containing an extract as an active ingredient. The composition for inhibiting oral bacteria according to claim 1, wherein the extraction solvent of the casualty shoot extract is water, C ₁ to C ₄ lower alcohol, or a mixture thereof. The composition for inhibiting oral bacteria according to claim 1, wherein the oral bacteria is Streptococcus mutans or Streptococcus sobrinus. The composition for inhibiting oral bacteria according to claim 1, wherein the composition is prepared in any one formulation selected from the group consisting of mouthwash, mouthwash, toothpaste, oral spray, toothbrush cleaner and denture cleaner. A quasi-drug for preventing or improving oral diseases containing Torilis japonica extract as an active ingredient. The quasi-drug for preventing or improving oral diseases according to claim 5, wherein the oral disease is tooth decay. The quasi-drug for preventing or improving oral diseases according to claim 6, wherein the tooth decay is a cavity caused by Streptococcus mutans or Streptococcus sobrinus. Casualty ( Torilis japonica ) A pharmaceutical composition for preventing or treating oral diseases containing an extract as an active ingredient. The pharmaceutical composition for preventing or treating oral diseases according to claim 8, wherein the oral disease is tooth decay. 10. The method of claim 9, wherein the tooth decay is Streptococcus mutans ( Streptococcus mutans ) Or Streptococcus sobrinus ( Streptococcus sobrinus ) Preventing or treating oral diseases, characterized in that the tooth decay caused by a pharmaceutical composition for the treatment. A feed additive for preventing or improving oral diseases containing Torilis japonica extract as an active ingredient. Casualty ( Torilis japonica ) A veterinary composition for preventing or treating oral diseases containing an extract as an active ingredient.